Back to Search
Start Over
1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC).
- Source :
-
Annals of Oncology . 2020 Supplement 6, Vol. 31, pS1241-S1242. 2p. - Publication Year :
- 2020
- Subjects :
- *NEOADJUVANT chemotherapy
*PEMBROLIZUMAB
*TRIPLE-negative breast cancer
Subjects
Details
- Language :
- English
- ISSN :
- 09237534
- Volume :
- 31
- Database :
- Academic Search Index
- Journal :
- Annals of Oncology
- Publication Type :
- Academic Journal
- Accession number :
- 152684534
- Full Text :
- https://doi.org/10.1016/j.annonc.2020.10.021